Neuromodulation Publishes 36-Month CORE-VNS Results Showing Sustained Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

LivaNova Reports 36-Month CORE-VNS Study Results Showing Sustained Seizure Reduction and Improved Quality of Life in Drug-Resistant Epilepsy LivaNova PLC, a medical technology company specializing in therapies for neurological and…

Read MoreNeuromodulation Publishes 36-Month CORE-VNS Results Showing Sustained Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

Brenus Pharma Reports Promising Safety and T-Cell Activation Data for STC-1010, With Two Complete Responses in First-Line MSS Metastatic Colorectal Cancer

Brenus Pharma Reports Promising Phase Ia Results for STC-1010 in Metastatic Colorectal Cancer, With 57% Objective Response Rate Brenus Pharma, a clinical-stage biotechnology company developing innovative immunotherapies for cancer, has…

Read MoreBrenus Pharma Reports Promising Safety and T-Cell Activation Data for STC-1010, With Two Complete Responses in First-Line MSS Metastatic Colorectal Cancer